RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RadNet reports strong Q4 earnings, targets AI growth in 2023

RadNet's Q4 2022 performance demonstrated strong revenue and EBITDA growth, fueled by procedural demand and strategic investments in AI and expansion initiatives.
Despite challenges like labor market disruptions and a net loss, the company's focus on innovation, market positioning, and financial discipline bodes well for future profitability and growth.
Opportunities lie in AI revenue growth, de novo center profitability, and market expansion, positioning RadNet as a key player in the radiology industry with a clear path to sustained success.
With a commitment to quality services, shareholder value, and operational excellence, RadNet's strategic vision aligns with industry trends and growth opportunities, setting the stage for continued success and market leadership.

RadNet reports record Q1 revenue and EBITDA growth, eyes AI expansion

RadNet's Q1 2023 showcased strong financial performance and operational improvements. Despite challenges like net loss and labor inflation, the company is strategically positioned for growth through expansion and AI initiatives. Opportunities in advanced imaging services and cancer detection technologies present avenues for future success.

RadNet reports record Q2 earnings, eyes growth amid challenges

RadNet's Q2 2023 performance reflects strong revenue and EBITDA growth, driven by core Imaging Center segment.
While facing challenges like potential Medicare cuts and AI segment delays, the company is optimistic about growth opportunities.
Strategic initiatives in preventative medicine, AI, and outpatient services position RadNet for future success.
With a focus on innovation and financial strength, RadNet aims to capitalize on market shifts and technological advancements.

RadNet reports robust Q3 earnings, eyes growth through AI and partnerships

RadNet's Q3 performance reflects strong revenue growth and financial management, supported by AI division success and strategic initiatives for 2024.
Despite challenges such as staffing shortages and pricing discussions, the company's strengths in liquidity, debt management, and operational focus position it well for future growth.
Opportunities in acquisitions, AI investments, and partnerships offer avenues for expansion and innovation, driving RadNet's market leadership and service excellence.
Overall, RadNet's focus on growth, efficiency, and strategic partnerships underscores its commitment to sustainable success and market resilience in the healthcare industry.

RadNet reports record Q4 earnings, eyes AI growth opportunities

RadNet's Q4 2023 performance was strong, with record revenue and adjusted EBITDA driven by Imaging Center segment growth.
The company's focus on AI, acquisitions, and joint ventures presents growth opportunities but also challenges in reaching expansion targets.
Management's commitment to market leadership and financial strength positions RadNet well for future success and innovation.
RadNet's strategic investments and balance sheet strength support its growth initiatives and potential breakthroughs in AI solutions.

RadNet achieves record Q3 results, eyes AI growth opportunities

RadNet's Q3 2024 performance showcased exceptional financial results, underpinned by revenue growth, operational efficiency, and strategic guidance revisions for the full year.
The company's strengths lie in expansion initiatives, innovative collaborations, and a forward-looking approach towards technology commercialization and digital health advancement.
While facing challenges in regional adoption rates and program implementations, RadNet is well-positioned to capitalize on opportunities through strategic partnerships, AI profitability, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2023 Conference on Wednesday, September 20th at 4:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Sidoti & Company Fall 2023 Virtual Conference on Wednesday, September 20th

DaVita

Encompass Health

Option Care Health

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and RDNT are well-poised to gain.

4 Stocks to Buy in a Booming Outpatient Home Health Industry

LivePerson

FutureTech II Acquisition Corp

Except for companies like Microsoft (NASDAQ: MSFT ) and Nvidia (NASDAQ: NVDA ), I don't think it would be out of line for regular Investors to consider most artificial intelligence stocks to be speculative by nature. This has led to AI stocks to avoid.

3 Super Speculative AI Stocks Not Worth the Risk

RadNet, Inc. (NASDAQ:RDNT ) Q2 2023 Earnings Call Transcript August 8, 2023 10:30 AM ET Company Participants Mark Stolper - Executive VP & CFO Howard Berger - Chairman, President & CEO Conference Call Participants Brian Tanquilut - Jefferies LLC Nathan Malewicki - Raymond James Yuan Zhi - B. Riley Securities Mitra Ramgopal - Sidoti Operator Good day and welcome to the RadNet Second Quarter 2023 Financial Results Conference Call.

RadNet, Inc. (RDNT) Q2 2023 Earnings Call Transcript

RadNet (RDNT) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.15 per share a year ago.

RadNet (RDNT) Q2 Earnings and Revenues Top Estimates

LOS ANGELES, Aug. 08, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2023.

RadNet Reports Second Quarter Financial Results, with Record Quarterly Revenue and Adjusted EBITDA(1), and Updates 2023 Financial Guidance Ranges

LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) announced today the addition of two executives to lead advancements in the company's technology solutions, including its current portfolio of radiology informatics (eRAD Radiology Information and Image Management Systems and related solutions) and clinical and generative Artificial Intelligence (AI). Sham Sokka, PhD., has been named Chief Operating and Technology Officer of Digital Health at RadNet. Sanjog Misra has joined the company as Chief Commercial Officer of Digital Health.

RadNet, Inc. Announces the Addition of Sham Sokka and Sanjog Misra to Drive Further Growth Within its Digital Health Initiatives

ExScientia Ltd

Schrodinger 

But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant investment in OpenAI, developer of ChatGPT.

Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential

LOS ANGELES, July 21, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its second quarter 2023 financial results on Tuesday, August 8th, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Second Quarter 2023 Financial Results Conference Call

RadNet has seen a 13.5% increase in capital appreciation due to growing procedure volumes and overall profitability, with the position up 50.6% since August 2022. RDNT's Q1 FY'23 showed attractive growth percentages in imaging volumes, with double-digit gains across the board. Net-net, reiterate buy, still eyeing $40/share, a potential 30% upside.

RadNet: Growing Procedure Volumes - Significant Upside Potential

LOS ANGELES, June 16, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today the closing of its underwritten public offering of 8,711,250 shares of its common stock at a price to the public of $29.75 per share, which includes the entire overallotment option to the underwriters of 1,136,250 shares. The gross proceeds to RadNet from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $259.2 million.

RadNet Announces Closing Of Upsized Public Offering Of Common Stock

LOS ANGELES, June 13, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today the pricing of its underwritten public offering of 7,575,000 shares of its common stock at a price to the public of $29.75 per share. The gross proceeds to RadNet from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $225 million. In addition, RadNet has granted the underwriters a 30-day option to purchase up to an additional 1,136,250 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 16, 2023, subject to satisfaction of customary closing conditions.

RadNet Announces Pricing of Upsized Public Offering of Common Stock

LOS ANGELES , June 13, 2023 /PRNewswire/ -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $175,000,000 of shares of common stock. In addition, RadNet intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 shares of common stock.

RADNET ANNOUNCES PROPOSED $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

LOS ANGELES, June 05, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2023 Global Healthcare Conference on Thursday, June 8, 2023 at 3:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Jefferies 2023 Global Healthcare Conference on June 8, 2023

RadNet, Inc. (NASDAQ:RDNT ) Q1 2023 Earnings Conference Call May 9, 2023 10:30 AM ET Company Participants Howard Berger - Chairman, President & CEO Mark Stolper - Executive VP & CFO Conference Call Participants Brian Tanquilut - Jefferies LLC John Ransom - Raymond James Lawrence Solow - CJS Securities Operator Good morning, and welcome to the RadNet, Inc. First Quarter 2023 Financial Results Call. All participants will be in a listen-only mode.

RadNet, Inc. (RDNT) Q1 2023 Earnings Call Transcript

RadNet (RDNT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.15 per share a year ago.

RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates

LOS ANGELES, May 09, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers, today reported financial results for its first quarter of 2023.

RadNet Reports First Quarter Financial Results with Record First Quarter Revenue and Adjusted EBITDA(1) from Imaging Center Operations and Revises Upwards 2023 Financial Guidance Ranges for Revenue and Adjusted EBITDA(1)

ANNAPOLIS, Md., May 04, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), today announced that Maryland Governor Wes Moore signed into law legislation to improve lung and breast cancer detection and diagnosis in Maryland. House Bill (HB) 815/Senate Bill (SB) 965 and HB 376/SB 184 require state-regulated insurers to waive patient cost-shares for supplemental diagnostic imaging associated with lung and breast cancers, respectively. The bills were championed by RadNet and received unanimous support from the Maryland House and Senate.

Maryland Governor Moore Signs RadNet-supported Legislation to Make Follow-up Diagnostic Imaging for Breast and Lung Cancers More Affordable

LOS ANGELES, May 01, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc., (NASDAQ: RDNT) today announced that it has received FDA clearance for the third-generation release of its Quantib Prostate™ 3.0 MRI artificial intelligence (AI) software, further enhancing the offering with new and updated tools. Quantib Prostate™ software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.

RadNet's Quantib B.V. Subsidiary Receives FDA Clearance for its Quantib Prostate™ 3.0 Software

LOS ANGELES, April 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2023 financial results on Tuesday, May 9, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its First Quarter 2023 Financial Results Conference Call

RadNet, Inc. has projected itself to have a strong FY'23 from a period of heavy investment last year. The firm has added numerous de novos and expects to bring more online this year.

RadNet: In For A Big FY 2023, Look For De Novo Contributions

Pennant Group Inc

Viemed Healthcare

Increasing interest rates, higher costs and rising unemployment paint an unfavorable picture with the risk of a recession looming large. Here we discuss three medical stocks that may be good bets even in a recession.

3 Medical Device Stocks With Potential to Fight Recession Risk

Addus HomeCare

Chemed

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

4 Promising Stocks From a Challenging Outpatient Home Health Industry

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2023 Conference on Wednesday, March 22nd at 01:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Sidoti & Company 2023 Virtual Spring Investor Conference on Wednesday, March 22nd

RadNet (RDNT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

News for RadNet Stock (RDNT)